skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Allogeneic AML Antigen-expressing Dendritic Cell Vaccine (Code C97265)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Allogeneic AML Antigen-expressing Dendritic Cell Vaccine

Definition: A cancer vaccine consisting of allogeneic, immortalized dendritic precursor cells derived from a patient with acute myelogenous leukemia (AML), with potential immunostimulatory and antineoplastic activities. Upon ex vivo stimulation and expansion of the precursor cells into mature, fully functional dendritic cells (DCs) and subsequent administration, the allogeneic AML antigen-expressing DC vaccine may elicit a potent cytotoxic T-cell (CTL) and antibody response against AML antigen-expressing cells, resulting in tumor cell death.

Label: Allogeneic AML Antigen-expressing Dendritic Cell Vaccine

NCI Thesaurus Code: C97265 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL429791  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Allogeneic Acute Myeloid Leukemia Antigen-expressing Dendritic Cell Vaccine
Allogeneic AML Antigen-expressing Dendritic Cell Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 702662
PDQ Open Trial Search ID 702662 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C97265
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom